Tag
This study evaluates risk factors for intracranial haemorrhage after tenecteplase fibrinolysis in STEMI patients, developing a prediction model highlighting age, blood pressure, sex, weight, and dose interactions as key determinants.
In patients with distal and medium vessel occlusion strokes, tenecteplase achieves higher early recanalization rates and reduces early infarct growth compared to alteplase, supporting its preferential use in this clinical setting.
Secondary analysis of the TASTE trial reveals tenecteplase confers superior functional outcomes versus alteplase in patients with distal middle cerebral artery occlusions, supporting its use in more peripheral ischemic stroke territories.
A post hoc analysis of the BRIDGE-TNK trial reveals that intravenous tenecteplase before endovascular thrombectomy significantly improves functional independence in acute large-vessel occlusion stroke patients with extensive baseline ischem
Secondary analysis of the TEMPO-2 trial reveals that successful recanalization significantly improves 90-day functional outcomes in minor ischemic stroke patients with proven occlusion, with tenecteplase markedly enhancing recanalization ra
In a randomized trial of large-vessel-occlusion stroke, standard-dose tenecteplase improved early reperfusion before thrombectomy compared with low-dose alteplase, with similar safety and functional outcomes.
In patients with large-vessel-occlusion stroke undergoing thrombectomy, standard-dose tenecteplase achieved more early reperfusion than low-dose alteplase, with similar safety and functional outcomes.
The TRACE-5 trial demonstrates that tenecteplase significantly improves functional outcomes for patients with basilar artery occlusion within 24 hours of onset, offering a safe and effective extension of the therapeutic window for this high
The OPTION trial reveals that tenecteplase administered 4.5 to 24 hours post-stroke in patients with non-large vessel occlusion and salvageable tissue significantly improves functional recovery, although it carries a higher risk of symptoma
The TenCRAOS trial demonstrated that intravenous tenecteplase administered within 4.5 hours of acute central retinal artery occlusion does not improve vision recovery compared to aspirin and carries significant safety risks, including fatal
The TENET randomized clinical trial reveals that tenecteplase bolus administration achieves significantly higher thrombolytic success rates and shorter hospital stays compared to alteplase infusion for mechanical prosthetic valve thrombosis
A secondary analysis of the TEMPO-2 trial shows that intravenous tenecteplase does not improve 90-day outcomes in minor disabling stroke defined by NIHSS scores, highlighting the need to reconsider thrombolysis in this patient population.
Three major Chinese trials examine intravenous and intra-arterial tenecteplase as adjuncts to thrombectomy in acute large-vessel occlusion stroke, revealing functional benefit with intravenous use before thrombectomy but not after reperfusi
The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant
The ANGEL-TNK trial found that intra-arterial tenecteplase after successful endovascular thrombectomy improved excellent neurological outcomes at 90 days without increasing bleeding or mortality, but secondary outcomes showed no significant
